arrow
C

Christopher J. Gibson

Dana-Farber Cancer Institute
H指数:44
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial

在关键性随机试验中,CPX-351选择性地使AML和脊髓发育不良相关突变患者受益

2026-02-040
OAAI
Human plasma proteomic profile of clonal hematopoiesis

克隆性造血的人类血浆蛋白质组谱

2025-11-270
OAAI
Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia

慢性淋巴细胞白血病患者的不确定潜能的髓系克隆造血

2024-11-270
OAAI
PRECLINICAL DEVELOPMENT OF KYV-201, AN INVESTIGATIONAL ALLOGENEIC ANTI-CD19 CAR T CELL FORTHE TREATMENT OFAUTOIMMUNE DISEASE

KYV-201的临床前开发,KYV-201是一种用于治疗自身免疫性疾病的同种异体抗CD19 CAR T细胞。

2024-06-011
PRE
Detection and dynamic monitoring of clonal hematopoiesis mutations in women receiving systemic therapies for high grade serous ovarian carcinoma
2024-03-040
PRE
Association of Somatic TET2 Mutations With Giant Cell Arteritis

体细胞TET2突变与巨细胞动脉炎的关系

2024-02-027
OAAI
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation (vol 30, pg 1503, 2023)
2024-02-010
OA
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
2023-12-266
OAAI
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
2023-11-0110
PRE
Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk

炎症和克隆造血相关心血管风险的遗传修饰

2023-09-1519
OAAI
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy
2023-04-126
OA
Clonal haematopoiesis and risk of chronic liver disease

克隆性造血与慢性肝病风险

Nature
IF48.5
2023-04-120
PRE
Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study
2023-03-010
PRE
TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease
2023-01-1649
OA
?ADVANCE? (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
2023-01-016
OA